PRMT5 and neoplasm: Furthermore, Hu et al. found in their study that inhibition of PRMT5 by shRNA or pharmacological approaches attenuated tumor progression and caused enhanced PD-L1 expression and improved response to immune checkpoint inhibitors [50].